Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1805 results
September 2017
-
Media ReleaseNovartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety dataCosentyx® (secukinumab) is the first and only fully human IL-17A inhibitor to show sustained skin clearance rates at 5 years in phase III in psoriasis[1] Landmark data show that PASI…
-
Media ReleaseSandoz proposed biosimilar rituximab accepted for review by the FDARituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis[1] Sandoz believes the comprehensive data package submitted to the FDA for review confirms…
-
Media ReleaseNovartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanomaThe three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo[1] Consistent improvement in RFS observed across all pre-specified…
-
Media ReleaseNovartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapiesAMG 334 (erenumab) delivered consistent reductions in monthly migraine days for patients with chronic migraine and prior treatment failure, a population with significant unmet need Dedicated…
-
In The NewsChanging the worldNovartis was ranked 4th in Fortune magazine’s Change the World list and cited for developing an innovative new cancer treatment, working to expand access to healthcare and supporting value-based…
-
Media ReleaseNovartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MSPhase III PARADIGMS study in pediatric MS met its primary endpoint, showing a significant reduction in relapses occur with fingolimod versus interferon beta-1a There is a significant unmet…
-
Media ReleaseNovartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.Basel, September 4, 2017 - Joseph Jimenez, Chief Executive Officer (CEO) of Novartis, has informed the Board of Directors of his desire to step down as CEO in 2018, after eight years in position. The…
August 2017
-
Media ReleaseNovartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twiceFirst-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes [1],[2]. Novel approach to cancer…
-
Media ReleaseNovartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies plannedReview of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS is…
-
Media ReleaseNovartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular riskStudy showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people with a prior heart attack and inflammatory atherosclerosis who were treated with 150mg of ACZ885, in…
-
Media ReleaseNovartis appoints Bertrand Bodson as Chief Digital OfficerNew leader to drive the digital transformation Novartis has embarked upon Basel, August 24, 2017 - Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury'…
-
Media ReleaseNovartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitorApproval is based on pivotal MONALEESA-2 trial, which showed Kisqali plus letrozole reduced risk of disease progression or death by 43% versus letrozole alone[1] Kisqali plus letrozole…
Pagination
- ‹ Previous page
- 1
- …
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- …
- 151
- › Next page